Lavipharm S.A. (ATH:LAVI)

Greece flag Greece · Delayed Price · Currency is EUR
1.530
+0.080 (5.52%)
Apr 28, 2026, 5:11 PM EET
89.12%
Market Cap 244.60M
Revenue (ttm) 62.58M
Net Income (ttm) 5.99M
Shares Out 168.69M
EPS (ttm) n/a
PE Ratio 40.84
Forward PE n/a
Dividend 0.02 (1.38%)
Ex-Dividend Date n/a
Volume 824,017
Average Volume 309,021
Open 1.444
Previous Close 1.450
Day's Range 1.444 - 1.548
52-Week Range 0.734 - 1.548
Beta 0.85
RSI 71.81
Earnings Date Apr 23, 2026

About Lavipharm

Lavipharm S.A. engages in the research, development, manufacture, import, marketing, sale, and wholesale of pharmaceutical, cosmetics, and healthcare products to physicians and pharmacists in Greece and internationally. The company offers pharmaceutical products for cardiology, oncology-urology, central nervous system, chronic pain, and self- treatment. It also provides prescription medicines and over the counter (OTC) products, as well as LIFELAB CBD products. The company was founded in 1911 and is based in Paiania, Greece. [Read more]

Industry Drug Manufacturers - Specialty & Generic
Sector Healthcare
Founded 1911
Employees 282
Stock Exchange Athens Stock Exchange
Ticker Symbol LAVI
Full Company Profile

Financial Performance

In 2025, Lavipharm's revenue was 62.58 million, an increase of 18.20% compared to the previous year's 52.95 million. Earnings were 5.99 million, a decrease of -33.31%.

Financial Statements

News

There is no news available yet.